The University of Chicago Header Logo

Mark J. Ratain

Concepts (1156)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
167
2024
2360
14.710
Why?
Neoplasms
191
2024
2898
14.460
Why?
Pharmacogenetics
76
2024
434
10.230
Why?
Glucuronosyltransferase
50
2015
184
6.710
Why?
Camptothecin
53
2020
189
6.440
Why?
Antineoplastic Combined Chemotherapy Protocols
69
2021
2438
4.790
Why?
Antineoplastic Agents, Phytogenic
45
2014
276
4.740
Why?
Clinical Trials, Phase II as Topic
24
2022
176
4.740
Why?
Clinical Trials, Phase I as Topic
32
2022
155
4.310
Why?
Humans
541
2024
86678
4.000
Why?
Clinical Trials as Topic
42
2020
1169
3.700
Why?
Medical Oncology
17
2022
359
3.460
Why?
Pyridines
19
2022
310
3.310
Why?
Research Design
30
2022
594
3.200
Why?
Antibodies, Monoclonal, Humanized
18
2023
930
3.090
Why?
Drug-Related Side Effects and Adverse Reactions
13
2022
199
2.770
Why?
Food-Drug Interactions
8
2017
18
2.760
Why?
Lung Neoplasms
25
2023
2262
2.750
Why?
Dose-Response Relationship, Drug
65
2022
1961
2.740
Why?
Carcinoma, Non-Small-Cell Lung
18
2023
1075
2.730
Why?
Protein Kinase Inhibitors
16
2022
589
2.640
Why?
Polymorphism, Genetic
31
2021
819
2.500
Why?
Benzenesulfonates
12
2012
66
2.470
Why?
Drug Approval
6
2023
62
2.440
Why?
Randomized Controlled Trials as Topic
18
2022
865
2.430
Why?
Maximum Tolerated Dose
26
2022
270
2.420
Why?
Piperidines
7
2022
181
2.310
Why?
Aged
206
2021
18423
2.310
Why?
Drug Labeling
9
2017
41
2.140
Why?
Drug Administration Schedule
58
2020
916
2.110
Why?
Middle Aged
219
2021
25040
2.090
Why?
Adenine
12
2022
85
2.090
Why?
Genotype
53
2022
1852
2.010
Why?
Prostatic Neoplasms, Castration-Resistant
5
2018
111
1.970
Why?
Male
241
2024
40988
1.960
Why?
Antimetabolites, Antineoplastic
14
2020
236
1.930
Why?
United States Food and Drug Administration
13
2024
127
1.920
Why?
Drugs, Investigational
11
2018
37
1.870
Why?
Economics, Pharmaceutical
3
2023
9
1.870
Why?
Enzyme Inhibitors
13
2017
639
1.860
Why?
Polymorphism, Single Nucleotide
35
2021
2357
1.840
Why?
Androstenes
5
2021
43
1.840
Why?
Sirolimus
7
2018
170
1.840
Why?
Drug Interactions
24
2022
248
1.840
Why?
Female
246
2023
44550
1.820
Why?
Biomarkers, Tumor
20
2021
1464
1.820
Why?
Biopsy
11
2022
1163
1.820
Why?
Precision Medicine
19
2022
395
1.810
Why?
Pharmacogenomic Testing
16
2022
97
1.810
Why?
Adult
190
2022
25659
1.790
Why?
Aged, 80 and over
87
2021
6513
1.770
Why?
Fluorouracil
29
2021
556
1.770
Why?
Neutropenia
28
2019
215
1.690
Why?
Deoxycytidine
11
2019
237
1.650
Why?
Antineoplastic Agents, Immunological
5
2022
185
1.620
Why?
Paclitaxel
22
2021
460
1.520
Why?
Antibodies, Monoclonal
11
2021
1376
1.510
Why?
Biomedical Research
5
2023
376
1.510
Why?
Etoposide
17
2009
196
1.440
Why?
United States
37
2024
6681
1.440
Why?
Drug Industry
6
2021
54
1.440
Why?
Genome, Human
10
2019
756
1.410
Why?
Pharmacology, Clinical
4
2020
9
1.400
Why?
ErbB Receptors
8
2021
485
1.380
Why?
Treatment Outcome
59
2023
7998
1.380
Why?
Breast Neoplasms
25
2023
2903
1.340
Why?
Administration, Oral
31
2021
684
1.330
Why?
Cytochrome P-450 CYP2D6
9
2022
52
1.320
Why?
Patient Selection
11
2018
686
1.310
Why?
Microsomes, Liver
17
2017
49
1.290
Why?
Thrombocytopenia
18
2022
183
1.280
Why?
Endpoint Determination
10
2016
60
1.280
Why?
Suramin
11
2004
27
1.260
Why?
Sulfonamides
9
2017
300
1.260
Why?
Quinazolines
10
2010
220
1.260
Why?
Pyrimidines
6
2021
370
1.220
Why?
Infusions, Intravenous
38
2017
430
1.220
Why?
Melanoma
6
2020
459
1.210
Why?
Protein-Tyrosine Kinases
7
2012
302
1.210
Why?
Cisplatin
20
2021
612
1.170
Why?
Colorectal Neoplasms
16
2020
938
1.140
Why?
Phenylurea Compounds
16
2018
114
1.140
Why?
Drug Dosage Calculations
5
2020
16
1.130
Why?
Angiogenesis Inhibitors
10
2021
311
1.120
Why?
Food
4
2018
86
1.110
Why?
Ketoconazole
6
2017
25
1.100
Why?
Genome-Wide Association Study
24
2022
1621
1.100
Why?
Molecular Targeted Therapy
5
2018
266
1.090
Why?
Drug Prescriptions
8
2022
141
1.060
Why?
Kidney Neoplasms
13
2014
621
1.040
Why?
Pharmaceutical Preparations
5
2024
92
1.030
Why?
Genetic Therapy
2
2023
342
1.020
Why?
Glucuronides
14
2017
34
1.020
Why?
Genetic Variation
17
2020
1351
1.010
Why?
Tamoxifen
6
2018
168
1.010
Why?
Niacinamide
15
2014
116
1.000
Why?
Area Under Curve
28
2019
334
1.000
Why?
Models, Biological
26
2019
1749
1.000
Why?
HIV Protease Inhibitors
2
2022
21
0.990
Why?
Anemia
6
2022
128
0.980
Why?
Isoenzymes
9
2015
271
0.980
Why?
Imides
9
2001
26
0.980
Why?
Phosphotransferases
2
2017
65
0.970
Why?
Prospective Studies
27
2022
4214
0.970
Why?
Orphan Drug Production
1
2023
3
0.960
Why?
Isoquinolines
9
2001
72
0.950
Why?
Carcinoma, Renal Cell
11
2014
426
0.950
Why?
Drug Monitoring
8
2021
118
0.940
Why?
Carbolines
3
2022
8
0.930
Why?
Decision Support Systems, Clinical
5
2019
103
0.930
Why?
Heterocyclic Compounds, 4 or More Rings
3
2022
16
0.930
Why?
Leukemia, Hairy Cell
26
1994
186
0.930
Why?
Conflict of Interest
5
2015
67
0.920
Why?
Indoles
6
2017
318
0.920
Why?
Liver
18
2020
1230
0.910
Why?
Clinical Trials, Phase III as Topic
8
2015
172
0.910
Why?
Body Surface Area
6
2022
36
0.910
Why?
Ethics Committees, Research
2
2022
33
0.890
Why?
Prodrugs
5
2008
46
0.880
Why?
Leukemia
9
2021
320
0.870
Why?
Piperazines
3
2022
272
0.860
Why?
Quinoxalines
4
2014
50
0.860
Why?
Ritonavir
1
2022
12
0.850
Why?
Drug Costs
2
2020
62
0.840
Why?
Bevacizumab
13
2024
281
0.840
Why?
Arylamine N-Acetyltransferase
2
2021
11
0.840
Why?
Fear
1
2022
78
0.830
Why?
Liver Diseases
4
2007
241
0.830
Why?
Physicians
3
2021
674
0.830
Why?
Leucovorin
18
2021
218
0.830
Why?
Anemia, Sickle Cell
1
2023
131
0.820
Why?
Diarrhea
10
2009
182
0.820
Why?
Antibiotics, Antineoplastic
5
2012
114
0.820
Why?
Prostatic Neoplasms
13
2024
1721
0.820
Why?
Computer Simulation
6
2023
1078
0.820
Why?
Patents as Topic
1
2021
12
0.810
Why?
Janus Kinase 2
1
2021
57
0.810
Why?
Patient Harm
1
2021
7
0.810
Why?
Peripheral Nervous System Diseases
6
2020
85
0.810
Why?
Antifungal Agents
3
2007
117
0.800
Why?
Industry
3
2023
16
0.800
Why?
Health Care Costs
3
2021
239
0.790
Why?
Biological Products
2
2020
143
0.790
Why?
Cardiotoxicity
1
2021
9
0.780
Why?
Topotecan
9
2005
45
0.780
Why?
Methyltransferases
5
2013
182
0.780
Why?
Metabolic Clearance Rate
17
2017
121
0.770
Why?
Informed Consent
11
2022
266
0.770
Why?
Taxoids
6
2016
129
0.750
Why?
Multidrug Resistance-Associated Proteins
5
2013
27
0.740
Why?
Pharmacogenomic Variants
4
2021
41
0.730
Why?
Creatinine
6
2015
339
0.710
Why?
Cytochrome P-450 CYP3A
10
2017
43
0.710
Why?
Adenosine A2 Receptor Antagonists
1
2019
13
0.690
Why?
Cost-Benefit Analysis
6
2023
455
0.690
Why?
Research
4
2019
253
0.690
Why?
Triazoles
4
2012
96
0.680
Why?
Interleukin-6
1
2020
256
0.680
Why?
Topoisomerase II Inhibitors
4
2009
27
0.680
Why?
Programmed Cell Death 1 Receptor
1
2020
159
0.670
Why?
Doxorubicin
9
2007
295
0.670
Why?
TOR Serine-Threonine Kinases
5
2018
182
0.660
Why?
Interferon-alpha
16
2004
234
0.650
Why?
Caffeine
1
2019
81
0.640
Why?
Point-of-Care Systems
3
2019
141
0.640
Why?
National Cancer Institute (U.S.)
7
2023
70
0.640
Why?
Physician's Role
2
2017
179
0.630
Why?
Megestrol Acetate
1
2017
10
0.630
Why?
Metabolome
2
2017
47
0.630
Why?
Kidney Diseases
4
2007
418
0.620
Why?
Patient Education as Topic
2
2019
351
0.620
Why?
Parkinson Disease
1
2019
132
0.620
Why?
Protein Kinases
3
2009
209
0.620
Why?
Pyrazoles
5
2022
153
0.610
Why?
Hydroxamic Acids
3
2014
49
0.610
Why?
Practice Patterns, Physicians'
7
2021
584
0.600
Why?
Medical Order Entry Systems
1
2017
25
0.600
Why?
Dihydrouracil Dehydrogenase (NADP)
10
2006
29
0.590
Why?
Immunotherapy
2
2020
629
0.590
Why?
Nontherapeutic Human Experimentation
7
2017
20
0.590
Why?
Carboplatin
5
2021
286
0.590
Why?
Neovascularization, Pathologic
5
2018
353
0.590
Why?
Perioperative Care
5
2022
161
0.570
Why?
Guanine
4
2002
208
0.560
Why?
Recombinant Proteins
30
2017
1015
0.560
Why?
Germ-Line Mutation
7
2020
329
0.550
Why?
Leukopenia
12
2002
65
0.550
Why?
Capecitabine
6
2020
96
0.540
Why?
Pancreatic Neoplasms
4
2019
645
0.540
Why?
Drug Resistance, Neoplasm
9
2020
592
0.540
Why?
Guidelines as Topic
2
2019
162
0.530
Why?
Topoisomerase I Inhibitors
7
2020
33
0.530
Why?
RNA, Messenger
14
2018
1981
0.530
Why?
Attitude of Health Personnel
4
2019
636
0.530
Why?
Kidney
6
2015
1242
0.530
Why?
Oxidoreductases
10
2002
112
0.520
Why?
Introns
4
2013
289
0.520
Why?
Genetic Predisposition to Disease
15
2019
2271
0.520
Why?
Depsipeptides
1
2015
29
0.520
Why?
Aryl Hydrocarbon Hydroxylases
3
2013
44
0.520
Why?
Morpholines
1
2015
65
0.520
Why?
Meaningful Use
1
2014
2
0.520
Why?
Uracil
7
2002
72
0.520
Why?
Prostate-Specific Antigen
5
2018
353
0.520
Why?
Oligonucleotides, Antisense
2
2005
69
0.510
Why?
Head and Neck Neoplasms
10
2008
1052
0.500
Why?
Carbazoles
2
2005
51
0.500
Why?
Professional Practice
1
2015
46
0.500
Why?
Renal Insufficiency
2
2009
114
0.490
Why?
Time Factors
22
2020
5214
0.490
Why?
Lymphoma
7
2021
262
0.490
Why?
Cohort Studies
18
2019
2768
0.490
Why?
Hypertension, Pulmonary
3
2022
346
0.490
Why?
Bilirubin
13
2010
125
0.490
Why?
Reproducibility of Results
11
2021
2706
0.480
Why?
Regression Analysis
14
2010
596
0.480
Why?
Adenocarcinoma
5
2018
1169
0.480
Why?
Interferon Type I
17
1990
175
0.470
Why?
Sample Size
3
2011
130
0.470
Why?
Young Adult
22
2020
5980
0.470
Why?
Patient Protection and Affordable Care Act
1
2014
66
0.470
Why?
Linkage Disequilibrium
7
2013
473
0.460
Why?
Biological Availability
7
2017
92
0.460
Why?
Estrogen Antagonists
1
2013
48
0.460
Why?
Program Development
1
2014
125
0.460
Why?
Risk Assessment
19
2021
2264
0.460
Why?
Dietary Fats
1
2014
135
0.460
Why?
Drug Delivery Systems
2
2012
178
0.460
Why?
Hearing Loss
1
2013
56
0.450
Why?
Ambulatory Care
2
2014
181
0.450
Why?
Catechol O-Methyltransferase
1
2013
68
0.450
Why?
Proto-Oncogene Proteins c-raf
2
2004
47
0.450
Why?
Models, Statistical
8
2020
575
0.450
Why?
Food Labeling
1
2012
8
0.450
Why?
Drug Therapy
5
2016
70
0.450
Why?
Indazoles
5
2017
68
0.440
Why?
Phenotype
19
2020
2380
0.440
Why?
Cladribine
5
2004
35
0.440
Why?
Enzymes
2
2006
47
0.440
Why?
Vascular Endothelial Growth Factor A
5
2018
407
0.440
Why?
Universities
1
2013
135
0.430
Why?
Private Sector
2
2011
19
0.430
Why?
Practice Guidelines as Topic
7
2019
1037
0.430
Why?
Glucuronates
8
2007
22
0.420
Why?
Snake Venoms
2
2015
10
0.420
Why?
Medicine
3
2007
90
0.420
Why?
Clinical Protocols
2
2014
156
0.410
Why?
Investments
1
2011
6
0.410
Why?
Pyrazolones
2
2002
3
0.410
Why?
Warfarin
3
2019
103
0.410
Why?
Patient Safety
2
2020
212
0.410
Why?
Antineoplastic Agents, Hormonal
7
2018
150
0.410
Why?
Commerce
1
2011
29
0.400
Why?
Mass Media
1
2011
26
0.400
Why?
Vinblastine
7
1998
108
0.400
Why?
Neoplasm Staging
14
2021
1939
0.400
Why?
Technology, Pharmaceutical
2
2009
30
0.400
Why?
Haplotypes
7
2012
642
0.400
Why?
Academic Medical Centers
1
2014
380
0.400
Why?
Cost Sharing
1
2011
14
0.400
Why?
Germ Cells
1
2012
126
0.390
Why?
Interleukin-17
1
2011
101
0.390
Why?
Mutation
8
2021
3968
0.390
Why?
Hypertension
3
2021
1142
0.390
Why?
Kinetics
10
2017
1513
0.390
Why?
Clinical Decision-Making
5
2021
257
0.380
Why?
Gene Expression Regulation
5
2020
1921
0.380
Why?
Body Weight
4
2020
459
0.380
Why?
Renal Insufficiency, Chronic
1
2015
351
0.380
Why?
Insurance, Health, Reimbursement
1
2011
59
0.380
Why?
Eating
2
2012
166
0.380
Why?
Health Resources
1
2011
76
0.380
Why?
Cyclosporine
5
2007
234
0.380
Why?
Research Subjects
9
2007
73
0.380
Why?
Alleles
6
2017
1128
0.370
Why?
Patient Portals
2
2020
15
0.370
Why?
Aminopyridines
2
2022
38
0.360
Why?
Follow-Up Studies
15
2021
3642
0.360
Why?
Ovarian Neoplasms
3
2008
744
0.360
Why?
Cost Savings
2
2020
67
0.360
Why?
Drug Evaluation
17
2002
141
0.350
Why?
Population Groups
1
2009
41
0.350
Why?
Dinucleotide Repeats
1
2009
13
0.350
Why?
Hepatic Insufficiency
1
2009
1
0.350
Why?
Drug Design
8
2011
124
0.350
Why?
Acetylation
6
2021
121
0.350
Why?
Promoter Regions, Genetic
7
2012
937
0.350
Why?
Decision Support Techniques
2
2021
160
0.340
Why?
Fatigue
8
2022
174
0.340
Why?
Substrate Specificity
5
2017
347
0.340
Why?
Blood Pressure Monitoring, Ambulatory
1
2009
83
0.340
Why?
Cell Line, Tumor
9
2018
2426
0.340
Why?
Genetics, Population
2
2009
394
0.340
Why?
Drug Discovery
1
2009
103
0.330
Why?
Prescription Drugs
2
2019
36
0.330
Why?
Phosphorylcholine
1
2008
28
0.330
Why?
Organizations, Nonprofit
1
2008
8
0.330
Why?
Anesthesiology
2
2022
157
0.330
Why?
Biomarkers
2
2014
1718
0.330
Why?
Double-Blind Method
9
2019
1824
0.330
Why?
Biomedical Technology
1
2008
20
0.330
Why?
Immunosuppressive Agents
4
2007
977
0.330
Why?
Organoplatinum Compounds
4
2020
94
0.320
Why?
Cytochrome P-450 Enzyme System
7
2008
79
0.320
Why?
Data Interpretation, Statistical
5
2016
297
0.320
Why?
Disease Progression
6
2012
1532
0.320
Why?
Myelodysplastic Syndromes
3
2014
346
0.310
Why?
Drug Packaging
3
2020
7
0.310
Why?
Evidence-Based Medicine
5
2021
429
0.310
Why?
Government Regulation
2
2007
49
0.310
Why?
Salvage Therapy
4
2008
233
0.310
Why?
Genetic Privacy
1
2007
12
0.300
Why?
Tubulin Modulators
2
2020
24
0.300
Why?
Liposomes
2
2004
91
0.300
Why?
Decision Making
5
2018
642
0.300
Why?
Health Knowledge, Attitudes, Practice
3
2020
508
0.300
Why?
DNA-Binding Proteins
4
2012
1208
0.300
Why?
Models, Genetic
1
2012
926
0.300
Why?
Phenobarbital
4
2006
33
0.300
Why?
Prejudice
1
2007
49
0.290
Why?
Histone Deacetylase Inhibitors
3
2014
85
0.290
Why?
Medical Records
2
2007
119
0.290
Why?
Glomerular Filtration Rate
2
2011
385
0.290
Why?
Intestinal Absorption
3
2017
124
0.290
Why?
Delivery of Health Care
3
2023
426
0.280
Why?
Patient Acceptance of Health Care
2
2020
238
0.280
Why?
Naphthalimides
9
2001
17
0.280
Why?
Technology Transfer
1
2006
3
0.280
Why?
Radiosurgery
2
2021
272
0.280
Why?
Disease-Free Survival
8
2016
1204
0.280
Why?
Cytochrome P-450 CYP3A Inhibitors
2
2017
5
0.280
Why?
Erlotinib Hydrochloride
5
2010
90
0.280
Why?
Quantitative Trait Loci
5
2020
577
0.280
Why?
Organophosphonates
9
2001
50
0.280
Why?
Vascular Endothelial Growth Factor Receptor-2
3
2015
81
0.280
Why?
Drug Therapy, Combination
6
2019
895
0.270
Why?
Abiraterone Acetate
2
2018
11
0.270
Why?
Carcinoma, Hepatocellular
2
2013
386
0.270
Why?
Neoplasms, Hormone-Dependent
1
2005
40
0.270
Why?
Prognosis
14
2021
3680
0.270
Why?
O(6)-Methylguanine-DNA Methyltransferase
3
2002
118
0.270
Why?
Pharmacy and Therapeutics Committee
3
2010
5
0.270
Why?
Cytochrome P-450 CYP2C9
2
2019
21
0.260
Why?
Receptor, trkA
1
2005
14
0.260
Why?
Liver Neoplasms
3
2013
738
0.260
Why?
Survival Analysis
12
2018
1538
0.260
Why?
Neuroendocrine Tumors
1
2006
105
0.260
Why?
Receptor Protein-Tyrosine Kinases
2
2010
153
0.250
Why?
Anthraquinones
2
2002
8
0.250
Why?
Chicago
4
2014
1380
0.250
Why?
Dipeptides
1
2004
46
0.250
Why?
Maytansine
1
2004
9
0.250
Why?
Genomics
3
2019
720
0.250
Why?
Thionucleotides
2
2002
56
0.250
Why?
Information Dissemination
3
2019
103
0.250
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
5
2004
112
0.250
Why?
Clinical Medicine
3
2015
34
0.240
Why?
Fasting
2
2018
161
0.240
Why?
Patient Compliance
2
2005
228
0.240
Why?
Gene Expression Regulation, Enzymologic
4
2010
214
0.240
Why?
Risk Factors
12
2024
5420
0.240
Why?
Neoplasm Recurrence, Local
7
2018
1313
0.240
Why?
Acetyltransferases
2
2021
29
0.240
Why?
Granulocyte Colony-Stimulating Factor
7
2003
165
0.240
Why?
Glutathione Transferase
6
2005
111
0.240
Why?
Animals
25
2016
26590
0.240
Why?
Product Surveillance, Postmarketing
1
2023
37
0.240
Why?
Greenhouse Gases
1
2023
1
0.240
Why?
Genetic Markers
3
2018
476
0.230
Why?
Interleukin-2
7
2004
249
0.230
Why?
Pyrazines
4
2000
92
0.230
Why?
Government
1
2023
9
0.230
Why?
Physician-Patient Relations
4
2019
610
0.230
Why?
Sensory Receptor Cells
2
2014
35
0.220
Why?
Fever
3
2020
125
0.220
Why?
Neoplasms, Squamous Cell
2
2008
19
0.220
Why?
Prednisone
4
2018
258
0.220
Why?
Dioxolanes
1
2002
8
0.220
Why?
Survival Rate
10
2021
1864
0.220
Why?
Lymphoma, Non-Hodgkin
3
2010
261
0.220
Why?
Apoptosis
2
2008
1683
0.220
Why?
DNA Damage
2
2017
366
0.220
Why?
Chemistry, Pharmaceutical
2
2004
59
0.220
Why?
Metabolic Networks and Pathways
3
2013
79
0.210
Why?
Lactams
1
2022
10
0.210
Why?
DNA, Antisense
1
2002
15
0.210
Why?
Lactams, Macrocyclic
1
2022
14
0.210
Why?
ATP-Binding Cassette Transporters
2
2016
141
0.210
Why?
Alanine
2
2019
85
0.210
Why?
Transcription, Genetic
3
2017
1135
0.210
Why?
Triazines
2
2019
53
0.210
Why?
Tramadol
1
2022
14
0.210
Why?
Anilides
2
2013
47
0.210
Why?
Reimbursement, Incentive
1
2022
37
0.210
Why?
Leukemia, Myeloid
2
2014
249
0.210
Why?
Pain Management
2
2021
127
0.210
Why?
Kv1.3 Potassium Channel
1
2021
14
0.210
Why?
Celecoxib
2
2019
31
0.200
Why?
Uridine Diphosphate
2
1998
5
0.200
Why?
Oxidation-Reduction
3
2017
373
0.200
Why?
Genetic Testing
4
2019
535
0.200
Why?
Stomatitis
5
2004
30
0.200
Why?
Biotransformation
6
2009
50
0.200
Why?
Cytosine
1
2002
127
0.200
Why?
Mercaptopurine
3
2009
53
0.200
Why?
Oligodeoxyribonucleotides, Antisense
1
2001
16
0.200
Why?
Aminoquinolines
1
2001
17
0.200
Why?
Indenes
1
2001
9
0.200
Why?
Acrylamides
1
2021
30
0.200
Why?
Intercalating Agents
2
1993
12
0.200
Why?
Epothilones
2
2019
13
0.200
Why?
Human Genome Project
1
2001
19
0.200
Why?
Nitriles
2
2012
149
0.200
Why?
Proteinuria
1
2021
107
0.200
Why?
Patient Participation
4
2015
216
0.200
Why?
Hematologic Neoplasms
3
2014
329
0.200
Why?
Research Personnel
2
2001
67
0.200
Why?
Hockey
1
2021
9
0.200
Why?
Anesthetics
1
2021
48
0.200
Why?
Protein Kinase C
1
2002
270
0.190
Why?
Collagen
1
2002
269
0.190
Why?
Government Agencies
1
2020
10
0.190
Why?
Patient-Centered Care
1
2023
203
0.190
Why?
Anticarcinogenic Agents
3
2013
70
0.190
Why?
Antidotes
2
1997
23
0.190
Why?
Rheumatology
1
2021
29
0.190
Why?
Signal Transduction
6
2013
3243
0.190
Why?
Bile
2
2002
57
0.190
Why?
Organizational Policy
1
2001
55
0.190
Why?
Sarcoma
4
2009
215
0.190
Why?
Analgesics, Opioid
2
2021
413
0.190
Why?
Genotyping Techniques
3
2018
68
0.190
Why?
Albumins
2
2019
133
0.190
Why?
Safety
4
2010
152
0.190
Why?
Thymidylate Synthase
4
2003
13
0.190
Why?
Testicular Neoplasms
2
2019
105
0.190
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
2008
173
0.190
Why?
Peptide Fragments
1
2002
460
0.190
Why?
Remission Induction
17
2008
722
0.190
Why?
Nausea
5
2022
175
0.190
Why?
Analgesics
1
2021
119
0.190
Why?
Societies, Medical
2
2019
573
0.190
Why?
Splenectomy
9
1992
82
0.190
Why?
Models, Theoretical
6
2014
482
0.180
Why?
Algorithms
3
2019
1830
0.180
Why?
Neoplasm Metastasis
10
2018
1056
0.180
Why?
Equivalence Trials as Topic
1
2019
5
0.180
Why?
Anesthesia
1
2022
164
0.180
Why?
Schools, Medical
1
2001
123
0.180
Why?
Europe
1
2020
309
0.180
Why?
DNA, Neoplasm
3
2018
265
0.180
Why?
C-Reactive Protein
1
2020
190
0.180
Why?
Bone Marrow
12
2001
435
0.180
Why?
Drug Utilization
1
2020
65
0.180
Why?
Leukocytes, Mononuclear
4
2018
196
0.180
Why?
Circadian Rhythm
2
2015
303
0.180
Why?
Neoplasms, Second Primary
2
1992
252
0.180
Why?
Receptors, Cytoplasmic and Nuclear
2
2017
122
0.180
Why?
Inpatients
1
2022
298
0.180
Why?
Response Evaluation Criteria in Solid Tumors
2
2018
56
0.180
Why?
Chemotherapy, Adjuvant
5
2011
468
0.170
Why?
Leukocyte Count
10
1996
220
0.170
Why?
Cytidine Deaminase
1
2019
43
0.170
Why?
Hepatocytes
4
2013
127
0.170
Why?
Ethics, Medical
4
2008
306
0.170
Why?
Leukemia, Myeloid, Acute
4
2008
763
0.170
Why?
Tegafur
2
1999
17
0.170
Why?
Benzamides
2
2013
229
0.170
Why?
Stomach Neoplasms
1
2021
266
0.170
Why?
Lymphoproliferative Disorders
3
1996
107
0.170
Why?
Quality Indicators, Health Care
1
2020
145
0.170
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
2005
375
0.170
Why?
Withholding Treatment
1
2019
112
0.170
Why?
Exanthema
2
2009
36
0.170
Why?
Equilibrative Nucleoside Transporter 1
1
2018
2
0.170
Why?
Medication Adherence
1
2020
129
0.170
Why?
Bayes Theorem
1
2020
361
0.160
Why?
Receptors, IgG
1
2018
52
0.160
Why?
Singapore
1
2018
16
0.160
Why?
Cetuximab
4
2021
113
0.160
Why?
Receptors, Estrogen
3
2016
384
0.160
Why?
Phosphatidylinositol 3-Kinases
2
2016
262
0.160
Why?
Blood Pressure
3
2014
1144
0.160
Why?
Dehydroepiandrosterone
1
2018
51
0.160
Why?
Troleandomycin
1
2017
3
0.160
Why?
HSP90 Heat-Shock Proteins
1
2018
46
0.160
Why?
Bone Marrow Diseases
3
1993
40
0.160
Why?
Lymphocytes, Tumor-Infiltrating
1
2019
123
0.160
Why?
Proton Magnetic Resonance Spectroscopy
1
2017
12
0.160
Why?
Career Choice
1
2019
142
0.160
Why?
Liver Function Tests
4
2007
93
0.150
Why?
Erythropoietin
3
2013
91
0.150
Why?
Statistics as Topic
3
1993
238
0.150
Why?
History, 20th Century
2
2011
312
0.150
Why?
Receptors, Calcitriol
1
2018
129
0.150
Why?
Surveys and Questionnaires
9
2020
2504
0.150
Why?
Receptors, Vascular Endothelial Growth Factor
2
2014
70
0.150
Why?
Diphtheria Toxin
4
1998
20
0.150
Why?
Terminology as Topic
1
2019
217
0.150
Why?
Combined Modality Therapy
11
2021
1686
0.150
Why?
Adrenal Cortex Diseases
1
1996
6
0.150
Why?
Addison Disease
1
1996
4
0.150
Why?
Ribosomal Protein S6 Kinases, 70-kDa
2
2018
44
0.150
Why?
Specialization
2
2007
65
0.150
Why?
Motor Neuron Disease
1
1997
21
0.150
Why?
Valproic Acid
1
1997
24
0.150
Why?
Therapeutic Human Experimentation
2
1993
20
0.150
Why?
Neural Conduction
1
1997
69
0.150
Why?
Cardiovascular Agents
2
2015
56
0.150
Why?
Cytochrome P-450 CYP2C19
2
2014
7
0.150
Why?
Glioma
1
1999
285
0.140
Why?
Demyelinating Diseases
1
1997
68
0.140
Why?
Intersectoral Collaboration
1
2016
10
0.140
Why?
Periodicals as Topic
1
2019
168
0.140
Why?
Biliary Tract
1
1996
13
0.140
Why?
Metformin
1
2018
128
0.140
Why?
Testosterone
1
2018
271
0.140
Why?
Gene Expression Regulation, Neoplastic
4
2010
1197
0.140
Why?
Healthy Volunteers
1
2017
143
0.140
Why?
Critical Care
1
2019
370
0.140
Why?
Neoplasm Proteins
5
2016
532
0.140
Why?
Cyclophosphamide
7
2002
299
0.140
Why?
Atazanavir Sulfate
1
2015
1
0.140
Why?
Floxuridine
2
1993
11
0.140
Why?
Hyperbilirubinemia
1
2015
20
0.140
Why?
Jaundice
1
2015
14
0.140
Why?
Polyneuropathies
1
2016
27
0.140
Why?
Hydroxyurea
6
1998
239
0.140
Why?
Chromatography, High Pressure Liquid
5
2004
315
0.140
Why?
Drug Eruptions
2
2006
35
0.140
Why?
Flavonoids
4
2007
85
0.130
Why?
Tumor Microenvironment
1
2019
418
0.130
Why?
Glucocorticoids
1
2018
352
0.130
Why?
Random Allocation
6
2008
332
0.130
Why?
Attitude to Health
4
2017
220
0.130
Why?
Placebos
3
2017
218
0.130
Why?
Pneumonia, Viral
1
2020
316
0.130
Why?
Selection Bias
2
2011
37
0.130
Why?
Advisory Committees
1
2015
90
0.130
Why?
Collagen Type I
1
2015
62
0.130
Why?
Sulfonic Acids
1
1995
9
0.130
Why?
Treatment Failure
2
2011
286
0.130
Why?
Hydrocortisone
1
1996
298
0.130
Why?
Gene Expression Profiling
6
2013
1384
0.130
Why?
Nitrosamines
1
2014
8
0.130
Why?
Nedocromil
1
2014
6
0.130
Why?
Inactivation, Metabolic
2
2006
8
0.130
Why?
Loss of Heterozygosity
1
2014
85
0.130
Why?
Naphthyridines
1
2015
53
0.130
Why?
Sex Characteristics
1
1997
319
0.130
Why?
DNA Primers
2
2006
543
0.130
Why?
Comprehension
5
2000
79
0.130
Why?
Adolescent
11
2020
8984
0.130
Why?
Lymphopenia
2
2012
28
0.120
Why?
Busulfan
1
2014
39
0.120
Why?
Fees and Charges
1
2014
14
0.120
Why?
Phthalazines
1
2014
39
0.120
Why?
Drug Synergism
5
2018
303
0.120
Why?
Drug Resistance
3
1993
256
0.120
Why?
Epirubicin
3
2021
14
0.120
Why?
Aldehyde Oxidase
1
2014
3
0.120
Why?
Forced Expiratory Volume
1
2014
122
0.120
Why?
Neoplasms, Glandular and Epithelial
1
2015
74
0.120
Why?
Azacitidine
1
2014
137
0.120
Why?
Pyrroles
2
2015
184
0.120
Why?
Child
9
2020
6928
0.120
Why?
Cytochrome P-450 CYP2C8
1
2013
3
0.120
Why?
Receptors, Interleukin-2
5
1998
66
0.120
Why?
Disclosure
5
2000
108
0.120
Why?
Sex Factors
5
2020
1055
0.120
Why?
Thromboembolism
1
2014
119
0.120
Why?
Organic Cation Transporter 1
1
2013
1
0.120
Why?
Hepatocyte Nuclear Factor 1
1
2013
30
0.120
Why?
Portraits as Topic
1
2013
6
0.120
Why?
Anti-Asthmatic Agents
1
2014
76
0.120
Why?
Patient Outcome Assessment
1
2014
84
0.120
Why?
Carcinoma, Squamous Cell
2
1999
1077
0.120
Why?
Carcinoma, Small Cell
3
1997
134
0.120
Why?
Arteries
1
2014
177
0.120
Why?
Medicare
1
2017
410
0.120
Why?
Brain Diseases
1
1995
180
0.120
Why?
Comorbidity
1
2017
944
0.120
Why?
Erythropoiesis
1
2013
52
0.110
Why?
Brain Neoplasms
1
1999
763
0.110
Why?
Imatinib Mesylate
1
2013
126
0.110
Why?
Organic Anion Transporters, Sodium-Independent
1
2013
5
0.110
Why?
Axons
1
2014
174
0.110
Why?
Prevalence
1
2017
1239
0.110
Why?
Pathology, Molecular
1
2013
34
0.110
Why?
Leukemia, Prolymphocytic
1
1992
3
0.110
Why?
Transfection
4
2011
896
0.110
Why?
Adaptation, Physiological
1
1995
306
0.110
Why?
Health Policy
1
2015
180
0.110
Why?
Trastuzumab
2
2023
68
0.110
Why?
Off-Label Use
1
2012
16
0.110
Why?
Skin Neoplasms
5
2020
546
0.110
Why?
Leukemia, B-Cell
1
1992
23
0.110
Why?
Citrus paradisi
1
2012
5
0.110
Why?
Nicotine
1
2014
194
0.110
Why?
Conserved Sequence
1
2013
210
0.110
Why?
DNA Topoisomerases, Type II
2
2009
20
0.110
Why?
Quality of Life
5
2020
1585
0.110
Why?
Binding, Competitive
2
2010
145
0.110
Why?
Androstenols
1
2012
3
0.110
Why?
Kaplan-Meier Estimate
2
2011
861
0.110
Why?
Leukemia, Monocytic, Acute
1
1992
14
0.110
Why?
Multifactorial Inheritance
1
2014
159
0.110
Why?
Orchiectomy
1
2012
68
0.110
Why?
National Institutes of Health (U.S.)
2
2017
122
0.110
Why?
Cells, Cultured
3
2020
2819
0.110
Why?
Venous Thromboembolism
1
2014
153
0.100
Why?
Gene Dosage
2
2013
207
0.100
Why?
Hyperlipidemias
1
2012
95
0.100
Why?
Hydroxylation
2
2009
16
0.100
Why?
Students
1
2013
147
0.100
Why?
Logistic Models
4
1999
1188
0.100
Why?
Postmenopause
1
2012
98
0.100
Why?
Soft Tissue Neoplasms
2
2009
127
0.100
Why?
Hemoglobins
2
1991
179
0.100
Why?
Anticoagulants
2
2019
408
0.100
Why?
Therapeutic Equivalency
2
2021
12
0.100
Why?
Phosphorylation
2
2018
1106
0.100
Why?
Peptides
1
2015
639
0.100
Why?
Pentostatin
7
2002
30
0.100
Why?
Rats
5
2013
3992
0.100
Why?
Fibroblasts
1
2014
729
0.100
Why?
Proto-Oncogene Proteins c-ret
1
2011
21
0.100
Why?
Adenoma
1
2013
237
0.100
Why?
Thalidomide
1
2011
54
0.100
Why?
Patient Care
1
2012
100
0.100
Why?
Oligonucleotide Array Sequence Analysis
3
2008
689
0.100
Why?
Androstadienes
1
2011
72
0.100
Why?
Cyclosporins
1
1991
59
0.100
Why?
Reverse Transcriptase Polymerase Chain Reaction
3
2008
879
0.100
Why?
Maryland
1
2011
35
0.100
Why?
Tumor Cells, Cultured
4
2002
1041
0.100
Why?
Hyperglycemia
1
2012
176
0.100
Why?
Verapamil
1
1991
48
0.100
Why?
Multivariate Analysis
5
2009
1001
0.100
Why?
Life Expectancy
1
2011
86
0.100
Why?
Analgesics, Non-Narcotic
1
2011
46
0.100
Why?
Acetaminophen
1
2011
54
0.100
Why?
Pharmacoepidemiology
1
2010
6
0.100
Why?
Predictive Value of Tests
5
2021
1673
0.100
Why?
Feasibility Studies
5
2004
751
0.100
Why?
Gene Frequency
4
2008
677
0.100
Why?
Thyroxine
2
2015
344
0.100
Why?
DNA Repair
2
2003
356
0.100
Why?
Healthcare Disparities
1
2015
372
0.100
Why?
Insurance, Health
1
2012
160
0.100
Why?
Electroencephalography
1
1995
709
0.090
Why?
Hepatocyte Nuclear Factor 1-alpha
2
2009
80
0.090
Why?
Cholestasis
1
1990
47
0.090
Why?
Amino Acid Substitution
1
2011
339
0.090
Why?
Microtubules
2
2004
119
0.090
Why?
Efficiency
1
2010
40
0.090
Why?
Smoking
1
2014
609
0.090
Why?
Burkitt Lymphoma
1
2010
31
0.090
Why?
Glycosylation
1
2010
129
0.090
Why?
Severity of Illness Index
3
2020
1802
0.090
Why?
Antibodies, Monoclonal, Murine-Derived
1
2010
78
0.090
Why?
Proto-Oncogene Proteins B-raf
2
2013
138
0.090
Why?
Indinavir
2
2010
3
0.090
Why?
Half-Life
5
2008
96
0.090
Why?
Daunorubicin
2
2008
78
0.090
Why?
History, 21st Century
1
2011
175
0.090
Why?
Vomiting
4
2014
193
0.090
Why?
Rituximab
1
2010
116
0.090
Why?
Cardiovascular Diseases
2
2015
827
0.090
Why?
Cell Cycle Proteins
2
2010
388
0.090
Why?
Software
2
2017
654
0.090
Why?
Cell Proliferation
3
2016
1579
0.090
Why?
Motivation
4
2012
288
0.090
Why?
Kidney Function Tests
2
2007
124
0.090
Why?
Publishing
1
2010
90
0.090
Why?
Membrane Proteins
1
2016
1196
0.090
Why?
Lymphoma, B-Cell
1
2010
103
0.090
Why?
International Normalized Ratio
1
2009
38
0.090
Why?
Mucositis
1
2009
17
0.090
Why?
Podophyllotoxin
3
1994
10
0.090
Why?
Pain
2
2022
391
0.080
Why?
Blood Cell Count
6
1999
79
0.080
Why?
Polymerase Chain Reaction
2
2013
928
0.080
Why?
Werner Syndrome
1
2008
1
0.080
Why?
Topoisomerase Inhibitors
1
2008
2
0.080
Why?
Acute Disease
4
2014
826
0.080
Why?
RecQ Helicases
1
2008
6
0.080
Why?
Pilot Projects
4
2019
840
0.080
Why?
Forecasting
2
2008
305
0.080
Why?
Exodeoxyribonucleases
1
2008
14
0.080
Why?
Genes, Neoplasm
1
2008
37
0.080
Why?
Platinum Compounds
1
2008
31
0.080
Why?
Recombinant Fusion Proteins
4
1998
557
0.080
Why?
Developed Countries
1
2008
24
0.080
Why?
Health Care Sector
1
2008
13
0.080
Why?
Enterohepatic Circulation
1
2008
3
0.080
Why?
Personal Autonomy
4
1998
112
0.080
Why?
Hep G2 Cells
3
2013
48
0.080
Why?
MicroRNAs
1
2013
534
0.080
Why?
Colonic Neoplasms
1
2012
558
0.080
Why?
Protease Inhibitors
1
2008
72
0.080
Why?
Injections, Subcutaneous
3
2004
117
0.080
Why?
Stereoisomerism
3
2008
102
0.080
Why?
Immunotoxins
2
1998
14
0.080
Why?
Lymphoma, Follicular
1
2008
70
0.080
Why?
Economics, Medical
1
2007
6
0.080
Why?
Tomography, X-Ray Computed
2
2016
2601
0.080
Why?
Receptor, ErbB-2
2
2014
223
0.080
Why?
MAP Kinase Signaling System
1
2008
192
0.080
Why?
Phosphoproteins
1
2009
255
0.080
Why?
Carmustine
2
2000
70
0.080
Why?
Everolimus
1
2007
40
0.080
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2008
136
0.080
Why?
Hematopoietic Stem Cell Transplantation
1
2014
878
0.080
Why?
Gene Amplification
1
2007
131
0.080
Why?
Evolution, Molecular
1
2013
813
0.080
Why?
Insurance
1
2007
11
0.080
Why?
Hypotension
3
2004
70
0.070
Why?
Hodgkin Disease
1
2008
177
0.070
Why?
Tissue Distribution
2
2021
290
0.070
Why?
Age Factors
4
2014
1852
0.070
Why?
Employment
1
2007
52
0.070
Why?
Patient Reported Outcome Measures
2
2019
166
0.070
Why?
In Situ Hybridization, Fluorescence
2
2010
348
0.070
Why?
Adaptor Proteins, Signal Transducing
1
2009
302
0.070
Why?
Immunoenzyme Techniques
2
2002
303
0.070
Why?
Observer Variation
1
2008
603
0.070
Why?
Radiotherapy
2
2003
328
0.070
Why?
Base Sequence
3
2008
2330
0.070
Why?
Medication Errors
1
2007
39
0.070
Why?
Nogalamycin
1
1986
2
0.070
Why?
Tea
1
2006
19
0.070
Why?
Serum Albumin
3
1995
130
0.070
Why?
Molecular Structure
1
2007
287
0.070
Why?
Lymphoma, Large B-Cell, Diffuse
1
2008
151
0.070
Why?
Thymidine
1
1986
59
0.070
Why?
Catechin
1
2006
19
0.070
Why?
Photosensitivity Disorders
1
2006
15
0.070
Why?
Case-Control Studies
3
2020
1807
0.070
Why?
Cross-Over Studies
2
2011
399
0.070
Why?
Structure-Activity Relationship
1
2007
408
0.070
Why?
Keratosis
1
2006
21
0.070
Why?
Complementary Therapies
1
2007
54
0.070
Why?
Probability
1
2007
355
0.070
Why?
Asthma
1
2014
955
0.070
Why?
Infusion Pumps
5
1989
25
0.070
Why?
Retrospective Studies
8
2013
8496
0.070
Why?
DNA Topoisomerases, Type I
1
2006
23
0.070
Why?
Genes, ras
1
2006
96
0.070
Why?
Molecular Sequence Data
3
2008
3030
0.070
Why?
Drug Combinations
3
2010
224
0.070
Why?
Mice
6
2016
11356
0.070
Why?
Patients
1
2007
100
0.070
Why?
Foot Dermatoses
1
1985
3
0.070
Why?
Rats, Wistar
2
1997
297
0.070
Why?
Hand Dermatoses
1
1985
9
0.070
Why?
Protein Structure, Tertiary
1
2007
736
0.070
Why?
Neutrophils
3
2002
307
0.070
Why?
Alternative Splicing
2
2008
201
0.070
Why?
Adsorption
1
2005
54
0.070
Why?
Furans
1
2005
16
0.060
Why?
Oligodeoxyribonucleotides
1
2005
126
0.060
Why?
Filgrastim
2
2003
56
0.060
Why?
Consensus Sequence
1
2005
64
0.060
Why?
Phenylenediamines
1
2004
5
0.060
Why?
Meperidine
1
2004
13
0.060
Why?
Thiophenes
3
2000
48
0.060
Why?
Injections, Intravenous
3
2004
244
0.060
Why?
Oxidoreductases, N-Demethylating
1
2004
14
0.060
Why?
Cytochrome P-450 Enzyme Inhibitors
1
2004
10
0.060
Why?
Drug Hypersensitivity
1
2004
37
0.060
Why?
Capsules
1
2004
38
0.060
Why?
Transaminases
1
2004
34
0.060
Why?
Quinolones
1
2004
60
0.060
Why?
In Vitro Techniques
3
2015
989
0.060
Why?
B-Lymphocytes
2
2008
724
0.060
Why?
Mixed Function Oxygenases
1
2004
68
0.060
Why?
Coformycin
3
1989
9
0.060
Why?
Tissue Fixation
2
2014
40
0.060
Why?
Gene Transfer Techniques
1
2004
152
0.060
Why?
Paraffin Embedding
2
2014
78
0.060
Why?
Formaldehyde
2
2014
52
0.060
Why?
Pyrrolidines
1
2004
58
0.060
Why?
Neoplasm Transplantation
1
2004
391
0.060
Why?
Drug Screening Assays, Antitumor
2
2010
78
0.060
Why?
Research Support as Topic
1
2004
80
0.060
Why?
Greenhouse Effect
1
2023
1
0.060
Why?
Ethics, Research
1
2004
52
0.060
Why?
Mouth Mucosa
2
2014
67
0.060
Why?
Idoxuridine
2
1993
16
0.060
Why?
Hypnotics and Sedatives
1
2004
125
0.060
Why?
Pelvis
1
2003
95
0.060
Why?
Alkaline Phosphatase
4
2002
132
0.060
Why?
CD56 Antigen
1
2002
18
0.060
Why?
Chromium
1
2002
17
0.060
Why?
Child, Preschool
3
2020
3613
0.060
Why?
Endostatins
1
2002
6
0.060
Why?
Therapies, Investigational
1
2022
17
0.060
Why?
Pharmacists
1
2022
32
0.050
Why?
Hepatitis C
1
2005
210
0.050
Why?
CHO Cells
1
2002
187
0.050
Why?
Omeprazole
1
2022
11
0.050
Why?
Succinylcholine
1
2022
14
0.050
Why?
Hydralazine
1
2022
20
0.050
Why?
Syndrome
1
2003
446
0.050
Why?
Protein Kinase C-alpha
1
2002
27
0.050
Why?
Morphine
1
2003
130
0.050
Why?
Killer Cells, Natural
2
2002
267
0.050
Why?
X-ray Repair Cross Complementing Protein 1
1
2021
2
0.050
Why?
Epoprostenol
1
2022
46
0.050
Why?
Population
1
2002
35
0.050
Why?
Familial Primary Pulmonary Hypertension
1
2022
60
0.050
Why?
Flow Cytometry
2
2002
679
0.050
Why?
Immunohistochemistry
2
2004
1753
0.050
Why?
Oxycodone
1
2022
35
0.050
Why?
Anorexia
1
2001
30
0.050
Why?
Oligonucleotides
1
2002
92
0.050
Why?
Cricetinae
1
2002
560
0.050
Why?
Gastrointestinal Hemorrhage
1
2024
230
0.050
Why?
Point Mutation
1
2002
246
0.050
Why?
Carbon Radioisotopes
1
2001
35
0.050
Why?
Interinstitutional Relations
1
2001
28
0.050
Why?
Disease Models, Animal
1
2008
2231
0.050
Why?
Receptors, Interleukin-6
1
2020
17
0.050
Why?
Anthropometry
1
2001
74
0.050
Why?
Complement System Proteins
1
2001
81
0.050
Why?
Data Collection
2
2000
372
0.050
Why?
Cardiac Output
1
2001
156
0.050
Why?
Blood Coagulation
1
2001
91
0.050
Why?
Neurites
1
2020
35
0.050
Why?
Longitudinal Studies
2
2014
1019
0.050
Why?
Ferredoxin-NADP Reductase
1
2020
15
0.050
Why?
Sequence Analysis, DNA
2
2018
853
0.050
Why?
Aspartate Aminotransferases
1
2000
73
0.050
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2020
26
0.050
Why?
Carcinoma
1
2004
436
0.050
Why?
Proprotein Convertase 9
1
2020
20
0.050
Why?
Lactones
1
2000
28
0.050
Why?
Evaluation Studies as Topic
1
2000
274
0.050
Why?
Macrolides
1
2000
31
0.050
Why?
Interferons
4
1990
133
0.040
Why?
Glutathione
2
2000
104
0.040
Why?
Administration, Intravenous
1
2019
50
0.040
Why?
Colonic Polyps
1
2000
127
0.040
Why?
Gene Expression
2
2014
1284
0.040
Why?
Polyethylene Glycols
1
2001
364
0.040
Why?
Hypoxia
1
2004
641
0.040
Why?
Drug Recalls
1
2019
13
0.040
Why?
Codeine
1
2019
12
0.040
Why?
Health Plan Implementation
1
2019
56
0.040
Why?
Analysis of Variance
2
2004
912
0.040
Why?
Myosin Heavy Chains
1
2019
88
0.040
Why?
Feces
1
2001
319
0.040
Why?
Myosin Type II
1
2019
50
0.040
Why?
Hypolipidemic Agents
1
2020
102
0.040
Why?
Receptors, G-Protein-Coupled
1
2020
115
0.040
Why?
Hospitalization
2
2019
851
0.040
Why?
NFATC Transcription Factors
1
2018
29
0.040
Why?
Aldehyde Dehydrogenase
1
1998
14
0.040
Why?
Hematologic Diseases
2
1996
79
0.040
Why?
Mycosis Fungoides
1
1998
23
0.040
Why?
Alkyl and Aryl Transferases
1
1998
15
0.040
Why?
Ribonucleosides
2
1989
25
0.040
Why?
Crigler-Najjar Syndrome
1
1998
3
0.040
Why?
Organic Anion Transporters
2
2009
27
0.040
Why?
Zidovudine
1
1998
16
0.040
Why?
Cytochrome P-450 CYP2D6 Inhibitors
1
2018
5
0.040
Why?
Nitrophenols
1
1998
11
0.040
Why?
Human Umbilical Vein Endothelial Cells
1
2018
63
0.040
Why?
Anticonvulsants
1
1999
126
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2021
456
0.040
Why?
Treatment Refusal
1
1998
60
0.040
Why?
Program Evaluation
1
2019
297
0.040
Why?
Anti-Inflammatory Agents
1
2020
339
0.040
Why?
Exons
2
2011
450
0.040
Why?
Infant
2
2020
3047
0.040
Why?
Dose-Response Relationship, Radiation
1
2018
188
0.040
Why?
Causality
1
1998
81
0.040
Why?
Cancer Survivors
1
2019
85
0.040
Why?
DNA Methylation
1
2002
628
0.040
Why?
Alcohol Dehydrogenase
1
1997
42
0.040
Why?
Consent Forms
2
1995
11
0.040
Why?
Antihypertensive Agents
1
2022
521
0.040
Why?
Vinca Alkaloids
1
1997
3
0.040
Why?
Cosyntropin
1
1996
5
0.040
Why?
Multicenter Studies as Topic
2
2015
159
0.040
Why?
Pain, Postoperative
1
2019
240
0.040
Why?
Isotretinoin
1
1997
23
0.040
Why?
Thiotepa
2
2004
32
0.040
Why?
Radiotherapy Dosage
1
2018
468
0.040
Why?
Patient Satisfaction
1
2000
455
0.040
Why?
Health Personnel
1
2019
202
0.040
Why?
Adrenocorticotropic Hormone
1
1996
131
0.040
Why?
Aldosterone
1
1996
65
0.040
Why?
Tetrahydrofolates
1
1996
13
0.040
Why?
Hospital Mortality
1
2019
350
0.040
Why?
Disease Management
1
2019
327
0.040
Why?
Neoplasm Grading
1
2018
357
0.040
Why?
Morphine Derivatives
2
2008
8
0.040
Why?
Magnetic Resonance Imaging
1
2008
3362
0.040
Why?
User-Computer Interface
1
2017
185
0.040
Why?
Social Perception
1
2017
95
0.040
Why?
Antigens, Neoplasm
2
2009
325
0.030
Why?
Neuropsychological Tests
1
2018
502
0.030
Why?
Keratoacanthoma
1
1996
4
0.030
Why?
Mitoxantrone
1
1996
68
0.030
Why?
Biological Transport
2
2002
396
0.030
Why?
Vitamin D
1
2018
261
0.030
Why?
Lymphatic Metastasis
1
2018
486
0.030
Why?
Tertiary Care Centers
1
2016
94
0.030
Why?
Digestive System Diseases
1
1996
18
0.030
Why?
Life Tables
1
1995
48
0.030
Why?
Quality Control
1
2016
117
0.030
Why?
Transcription Factors
2
2014
1565
0.030
Why?
Transcriptional Activation
1
2016
280
0.030
Why?
Bleomycin
2
1993
98
0.030
Why?
Microsomes
1
2015
35
0.030
Why?
Membrane Transport Proteins
1
2016
166
0.030
Why?
Lung
2
2014
1169
0.030
Why?
Communication
1
2019
442
0.030
Why?
Interferon-gamma
2
1988
444
0.030
Why?
Chi-Square Distribution
1
1996
364
0.030
Why?
Cyclin-Dependent Kinase Inhibitor p15
1
2014
24
0.030
Why?
Bias
2
1995
127
0.030
Why?
Blast Crisis
1
1995
33
0.030
Why?
Rats, Sprague-Dawley
1
1998
1221
0.030
Why?
Chromatography, Liquid
2
2010
105
0.030
Why?
Immunocompromised Host
1
1996
140
0.030
Why?
Chromosome Mapping
2
2011
1074
0.030
Why?
Coma
1
1995
44
0.030
Why?
Blotting, Western
2
2008
782
0.030
Why?
Linear Models
1
1996
422
0.030
Why?
Body Mass Index
1
1998
770
0.030
Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2014
74
0.030
Why?
Myeloablative Agonists
1
2014
34
0.030
Why?
Peroxisome-Targeting Signal 1 Receptor
1
2014
3
0.030
Why?
Tumor Burden
1
2016
289
0.030
Why?
Nervous System Diseases
1
1995
151
0.030
Why?
Budesonide
1
2014
45
0.030
Why?
Prostate
1
2018
378
0.030
Why?
Antineoplastic Protocols
1
2014
9
0.030
Why?
Lymphocytes
3
2004
464
0.030
Why?
Prostatectomy
1
2018
471
0.030
Why?
Cyclohexanecarboxylic Acids
1
1994
17
0.030
Why?
Blindness
1
1994
41
0.030
Why?
Electronic Health Records
1
2017
320
0.030
Why?
Cell Line
2
2010
2469
0.030
Why?
DNA, Complementary
2
2007
393
0.030
Why?
Intracellular Signaling Peptides and Proteins
1
2016
379
0.030
Why?
Erythrocyte Count
1
2013
23
0.030
Why?
Body Height
1
2014
99
0.030
Why?
Arylsulfotransferase
1
2013
4
0.030
Why?
Reference Standards
1
2014
159
0.030
Why?
Clonal Evolution
1
2013
15
0.030
Why?
Sulfotransferases
1
2013
19
0.030
Why?
Proportional Hazards Models
2
2008
860
0.030
Why?
Blood Platelets
1
1994
149
0.030
Why?
Dacarbazine
1
1994
102
0.030
Why?
Odds Ratio
1
2015
680
0.030
Why?
Solute Carrier Organic Anion Transporter Family Member 1B3
1
2013
4
0.030
Why?
Drug Stability
1
2013
48
0.030
Why?
Anthracenes
1
1993
16
0.030
Why?
DNA Copy Number Variations
1
2014
171
0.030
Why?
Class I Phosphatidylinositol 3-Kinases
1
2013
56
0.030
Why?
Astrocytoma
1
1993
82
0.030
Why?
Regulatory Factor X Transcription Factors
1
2012
11
0.030
Why?
Frozen Sections
1
2013
48
0.030
Why?
Ethical Review
1
1992
8
0.030
Why?
Cattle
1
2013
376
0.030
Why?
Insurance Claim Review
1
2012
41
0.030
Why?
Blood
1
1993
69
0.030
Why?
Receptor, EphA5
1
2012
2
0.030
Why?
Blood Transfusion
2
1991
157
0.030
Why?
Databases, Factual
1
2016
816
0.030
Why?
Gene-Environment Interaction
1
2013
103
0.030
Why?
Imidazoles
1
2013
162
0.030
Why?
Sepsis
1
1996
306
0.030
Why?
Dogs
1
2013
686
0.030
Why?
ras Proteins
1
2013
128
0.030
Why?
Chromosomes, Human, Pair 21
1
1992
54
0.030
Why?
Insurance Benefits
1
2012
8
0.030
Why?
Chromosomes, Human, Pair 11
1
1992
106
0.030
Why?
Up-Regulation
1
2014
715
0.030
Why?
Least-Squares Analysis
1
1991
48
0.030
Why?
Hydrogen-Ion Concentration
1
2013
493
0.030
Why?
Intellectual Property
1
2011
3
0.030
Why?
Monocytes
3
1994
216
0.030
Why?
Evidence-Based Practice
1
2012
45
0.030
Why?
Species Specificity
1
2013
678
0.030
Why?
DNA Mutational Analysis
1
2013
526
0.030
Why?
Pan troglodytes
1
2013
197
0.030
Why?
Carcinoma, Merkel Cell
1
1991
16
0.020
Why?
Comparative Effectiveness Research
1
2012
53
0.020
Why?
Mice, Knockout
1
2016
1924
0.020
Why?
Luminescent Measurements
1
2011
57
0.020
Why?
Carcinoma, Neuroendocrine
1
2011
28
0.020
Why?
Taiwan
1
2011
23
0.020
Why?
3' Untranslated Regions
1
2011
92
0.020
Why?
Allelic Imbalance
1
2011
20
0.020
Why?
Glioblastoma
1
1993
255
0.020
Why?
Translocation, Genetic
1
1992
265
0.020
Why?
Genetic Loci
1
2012
250
0.020
Why?
Macaca mulatta
1
2013
459
0.020
Why?
Public Sector
1
2010
12
0.020
Why?
Microfilament Proteins
1
2012
208
0.020
Why?
Principal Component Analysis
1
2011
155
0.020
Why?
Toxicity Tests
1
2010
13
0.020
Why?
Receptors, Growth Factor
1
2010
52
0.020
Why?
Epigenesis, Genetic
1
2014
481
0.020
Why?
Gas Chromatography-Mass Spectrometry
2
2002
40
0.020
Why?
Antibody Formation
1
1991
171
0.020
Why?
Tandem Mass Spectrometry
1
2010
103
0.020
Why?
Hymecromone
1
2010
4
0.020
Why?
Glucuronic Acid
1
2010
11
0.020
Why?
Cloning, Molecular
1
2011
646
0.020
Why?
Imipramine
1
2010
16
0.020
Why?
Serine Endopeptidases
1
2010
145
0.020
Why?
Oncogene Proteins, Fusion
1
2010
128
0.020
Why?
Intestinal Mucosa
1
2015
797
0.020
Why?
Biocatalysis
1
2010
51
0.020
Why?
Gene Deletion
1
2011
329
0.020
Why?
Genetic Vectors
1
2011
439
0.020
Why?
Aging
1
1994
691
0.020
Why?
Microtubule-Associated Proteins
1
2010
176
0.020
Why?
Protein Binding
1
2013
1457
0.020
Why?
Mice, Inbred C57BL
1
2016
3095
0.020
Why?
Cooperative Behavior
1
2010
175
0.020
Why?
Demography
1
2009
177
0.020
Why?
Leukemia L1210
1
1988
12
0.020
Why?
DNA Breaks, Double-Stranded
1
2009
64
0.020
Why?
Proto-Oncogene Proteins c-met
1
2010
199
0.020
Why?
Survivors
1
2010
226
0.020
Why?
Melphalan
1
1989
98
0.020
Why?
Werner Syndrome Helicase
1
2008
1
0.020
Why?
Osteolysis
1
1988
14
0.020
Why?
Midazolam
1
2008
48
0.020
Why?
Thiones
2
2000
10
0.020
Why?
Sensitivity and Specificity
1
2013
1992
0.020
Why?
Antigens, Differentiation, T-Lymphocyte
1
1988
95
0.020
Why?
Rats, Inbred Dahl
1
2008
8
0.020
Why?
Complement C1q
1
2008
10
0.020
Why?
Transforming Growth Factor beta3
1
2008
16
0.020
Why?
Thiosemicarbazones
1
2008
6
0.020
Why?
Methemoglobinemia
1
2008
10
0.020
Why?
Recurrence
2
2008
1139
0.020
Why?
Health Services Accessibility
1
2012
394
0.020
Why?
Bone Marrow Transplantation
1
1989
286
0.020
Why?
Hypertrophy, Right Ventricular
1
2008
33
0.020
Why?
Lymphoma, T-Cell, Cutaneous
2
1998
12
0.020
Why?
Incidence
1
2012
1578
0.020
Why?
Luciferases, Firefly
1
2007
12
0.020
Why?
Karyotyping
1
1987
250
0.020
Why?
Xenobiotics
1
2007
7
0.020
Why?
Gadolinium DTPA
1
2008
261
0.020
Why?
Informatics
1
2007
5
0.020
Why?
Herb-Drug Interactions
1
2007
4
0.020
Why?
Cytarabine
1
2008
218
0.020
Why?
Antigens, Surface
1
1987
101
0.020
Why?
Molecular Diagnostic Techniques
1
2007
69
0.020
Why?
Mycophenolic Acid
1
2007
87
0.020
Why?
Aerosols
1
2007
44
0.020
Why?
Bone Marrow Examination
1
1987
48
0.020
Why?
Hydroxytestosterones
1
2006
1
0.020
Why?
Plant Preparations
1
2007
19
0.020
Why?
Mitogen-Activated Protein Kinases
1
2008
222
0.020
Why?
Pharmacokinetics
1
2006
12
0.020
Why?
Menogaril
1
1986
3
0.020
Why?
Genes, Reporter
1
2007
268
0.020
Why?
Infusions, Parenteral
1
1986
50
0.020
Why?
Uterine Cervical Neoplasms
1
1989
275
0.020
Why?
Thymine
1
1986
17
0.020
Why?
Hyponatremia
1
1986
25
0.020
Why?
Digestive System
1
1986
42
0.020
Why?
Administration, Inhalation
1
2007
188
0.020
Why?
Thyroid Neoplasms
1
2011
408
0.020
Why?
Enzyme Activation
1
2008
692
0.020
Why?
Empirical Research
2
1997
19
0.020
Why?
Vitamins
1
2007
81
0.020
Why?
Dietary Supplements
1
2007
128
0.020
Why?
Cell Survival
1
2008
969
0.020
Why?
Platelet Aggregation Inhibitors
1
2007
134
0.020
Why?
Mephenytoin
1
2004
2
0.020
Why?
Cytochrome P-450 CYP2B6
1
2004
6
0.020
Why?
Fluvoxamine
1
2004
6
0.020
Why?
Lung Diseases
1
2007
263
0.020
Why?
Receptors, Endothelin
1
2004
13
0.020
Why?
Sequence Deletion
1
2005
205
0.020
Why?
Hemodynamics
1
2008
711
0.020
Why?
Statistics, Nonparametric
1
2004
308
0.020
Why?
Vincristine
2
1997
111
0.010
Why?
Analgesia, Patient-Controlled
1
2003
16
0.010
Why?
Indicators and Reagents
1
2003
72
0.010
Why?
Contrast Media
1
2008
1078
0.010
Why?
Carrier Proteins
1
2007
673
0.010
Why?
Substance-Related Disorders
1
2007
394
0.010
Why?
Heart Ventricles
1
2008
760
0.010
Why?
Risk
1
2004
674
0.010
Why?
Dexamethasone
1
2004
326
0.010
Why?
Propofol
1
2002
89
0.010
Why?
Global Health
1
2002
193
0.010
Why?
Catalysis
1
2001
203
0.010
Why?
Cyclin-Dependent Kinases
1
2000
43
0.010
Why?
Hot Temperature
1
2000
206
0.010
Why?
Rectum
1
2000
146
0.010
Why?
Spectrophotometry, Ultraviolet
1
1998
44
0.010
Why?
Shivering
1
1998
4
0.010
Why?
Dermatitis, Exfoliative
1
1998
3
0.010
Why?
Methotrexate
2
1989
249
0.010
Why?
Pentoxifylline
1
1998
9
0.010
Why?
Platelet Count
2
1989
92
0.010
Why?
Cell Count
1
1998
195
0.010
Why?
Neoplasms, Experimental
1
1999
269
0.010
Why?
Persons
1
1997
6
0.010
Why?
Control Groups
1
1997
15
0.010
Why?
Federal Government
1
1997
29
0.010
Why?
Paternalism
1
1997
24
0.010
Why?
Vasodilator Agents
1
1998
152
0.010
Why?
Chromatography, Ion Exchange
1
1997
34
0.010
Why?
Patient Advocacy
1
1997
49
0.010
Why?
Acquired Immunodeficiency Syndrome
1
1997
78
0.010
Why?
Radiography
1
1999
813
0.010
Why?
Vulnerable Populations
1
1997
76
0.010
Why?
Ligands
1
1998
433
0.010
Why?
Neoplasm Invasiveness
1
1998
552
0.010
Why?
Mass Spectrometry
1
1997
189
0.010
Why?
Brain
1
1986
2216
0.010
Why?
Enzyme Induction
1
1995
88
0.010
Why?
Karnofsky Performance Status
1
1995
40
0.010
Why?
Menopause
1
1995
71
0.010
Why?
Catheterization, Central Venous
1
1996
116
0.010
Why?
CD4-CD8 Ratio
1
1994
18
0.010
Why?
Cultural Diversity
1
1995
51
0.010
Why?
Truth Disclosure
1
1995
87
0.010
Why?
Educational Status
1
1995
190
0.010
Why?
Cyclohexenes
1
1994
5
0.010
Why?
Benzofurans
1
1994
8
0.010
Why?
Lymphocyte Subsets
1
1994
64
0.010
Why?
Trust
1
1995
95
0.010
Why?
Professional Staff Committees
1
1992
7
0.010
Why?
Cancer Care Facilities
1
1992
28
0.010
Why?
Hemoglobin A
1
1992
8
0.010
Why?
2-Chloroadenosine
1
1992
5
0.010
Why?
Deoxyadenosines
1
1992
23
0.010
Why?
Platinum
1
1992
63
0.010
Why?
Diabetes Complications
1
1993
207
0.010
Why?
Respiratory Insufficiency
1
1993
150
0.010
Why?
Electrocardiography
1
1993
478
0.010
Why?
Absorption
1
1989
25
0.010
Why?
Acid Phosphatase
1
1988
33
0.010
Why?
Chlorambucil
1
1988
23
0.010
Why?
Chromatography, Gas
1
1988
28
0.010
Why?
Costs and Cost Analysis
1
1987
153
0.000
Why?
Platelet Transfusion
1
1986
14
0.000
Why?